57 Capital Advisors LLC (57CAP) is an investment management firm offering full fledge investment advisory services to Institutional and High Net Worth (HNW) clients.  We tailor each client's investment goals with a robust strategy and in depth research supported by a team of 7 Wall Street veterans.  We delivered an average 30% investment returns per annum over the last eight years.

​

57 Capital Management LLC (57CM) is a wholly owned private equity/venture capital investment subsidiary of 57CAP.  57CM aims to invest with global investors to capture the robust growth potentials in the healthcare market of China, the world’s second largest economy and most populous country.  Including its predecessor, 57CM has successfully invested in nine biotech and biopharmaceutical companies in China and US since 2012 with aggregated capital of RMB500M/US$80M.  With deep medical knowledge, these investments were made in cutting edge innovations in the key therapeutic areas of Neurology, Cardiology, Oncology and Infectious Diseases.

​

57CM also acts as cross border strategic advisor for Asia/China based outbound investors to make equity/debt investments in US and European healthcare companies.  

​

The principals of 57CAP and 57CM hold advanced degrees in medical and life sciences from world renowned universities, many with clinical research background in leading pharmaceutical companies.

​

57CAP and 57CM currently have offices in Singapore and New York.